Global Blood Therapeutics Inc. (NASDAQ:GBT) received a $47.00 price target from stock analysts at Roth Capital in a note issued to investors on Monday. The brokerage presently has a “buy” rating on the stock. Roth Capital’s target price suggests a potential upside of 161.11% from the stock’s previous close.

Several other research analysts have also recently weighed in on the stock. Wells Fargo & Co. started coverage on shares of Global Blood Therapeutics in a research report on Friday, September 30th. They set an “outperform” rating and a $23.05 price target on the stock. Morgan Stanley reissued a “buy” rating and set a $62.00 price target on shares of Global Blood Therapeutics in a research report on Sunday, August 14th. Wedbush reissued an “outperform” rating and set a $66.00 price target on shares of Global Blood Therapeutics in a research report on Wednesday, August 10th. Zacks Investment Research raised shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Tuesday, October 11th. Finally, Cowen and Company reissued an “outperform” rating and set a $83.00 price target (up previously from $80.00) on shares of Global Blood Therapeutics in a research report on Wednesday, October 26th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $47.86.

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ:GBT) traded up 3.60% on Monday, reaching $18.70. 195,690 shares of the company’s stock were exchanged. The stock’s market cap is $697.81 million. The firm has a 50 day moving average of $18.02 and a 200-day moving average of $19.20. Global Blood Therapeutics has a one year low of $12.24 and a one year high of $51.95.

Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Wednesday, November 9th. The company reported ($0.58) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.58). During the same quarter last year, the firm posted ($0.90) EPS. Equities research analysts forecast that Global Blood Therapeutics will post ($2.40) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Roth Capital Analysts Give Global Blood Therapeutics Inc. (GBT) a $47.00 Price Target” was originally reported by Financial Market News and is owned by of Financial Market News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at http://www.financial-market-news.com/roth-capital-analysts-give-global-blood-therapeutics-inc-gbt-a-47-00-price-target/1208833/.

A number of hedge funds and other institutional investors have recently bought and sold shares of GBT. TLP Group LLC acquired a new stake in shares of Global Blood Therapeutics during the third quarter worth about $111,000. American International Group Inc. raised its stake in shares of Global Blood Therapeutics by 104.2% in the second quarter. American International Group Inc. now owns 8,096 shares of the company’s stock worth $134,000 after buying an additional 4,131 shares during the period. Nationwide Fund Advisors raised its stake in shares of Global Blood Therapeutics by 101.7% in the second quarter. Nationwide Fund Advisors now owns 9,100 shares of the company’s stock worth $151,000 after buying an additional 4,588 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Global Blood Therapeutics during the second quarter worth about $181,000. Finally, Metropolitan Life Insurance Co. NY acquired a new stake in shares of Global Blood Therapeutics during the second quarter worth about $191,000. 56.01% of the stock is currently owned by institutional investors.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders.

5 Day Chart for NASDAQ:GBT

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.